Gilead’s herpes deal; FDA approvals for Boehringer, Roche
Plus, news about BioMarin and Cassava.
💊 Gilead opts into Assembly Bio’s genital herpes programs: As a result, Gilead will pay Assembly $35 million based …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Read More from Endpoints News